← boardnext 2026-12-30next 2026-12-31next 2027-08-08next 2027-12-31next 2028-05-31
SGIOF
Shionogidistress 0/10 · well-funded / low risk$17.550%today-32% from 52w high
Neurology 1
Lead: Solid Tumors
Revenue
$499677M
Liquidity
$1022145M
Runway
—
Shares 1y
—
Price & events
-1.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-1.5%
1W
-6.6%
1M
-8.1%
3M
-1.5%
6M
+10.7%
1Y
+40.9%
2Y
+7.9%
5Y
+6.7%
All
Overview
- Volume
- 0
- 52 Week Range
- $14.25 – $26.00
- Float Shares
- 850.63M
- % Held by Insiders
- 4.83%
- % Held by Institutions
- 60.81%
- Beta
- 0.04
Pipeline stages · 6 programs
S-337395
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Sivopixant, Acetazolamide, SASS-001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
S-606001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BPN14770
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
S-531011, Pembrolizumab, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Redasemtide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-30 Estimated 50% readout ~2027-02-13 | Phase 2 | S-337395 | Respiratory Syncytial Virus Infections | — | recruiting |
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 2 | Sivopixant, Acetazolamide, SASS-001 | Sleep Apnea | — | active not recruiting |
| 2027-08-08 Estimated 50% readout ~2027-09-22 | Phase 2 | S-606001 | Pompe Disease | — | recruiting |
| 2027-12-31 Estimated 50% readout ~2028-02-14 | Phase 2 | BPN14770 | Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder | — | active not recruiting |
| 2028-05-31 Estimated 50% readout ~2028-07-15 | Phase 1/2 | S-531011, Pembrolizumab, Bevacizumab | Solid Tumors | — | recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06-30 | Phase 2 | Redasemtide | Acute Ischemic Stroke | — | active not recruiting |
Catalyst news & presentations · 1
- 2026-07-30Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Solid Tumors
Recent news
- 2026-07-22Shionogi stock trades steady as recent earnings and pipeline drive long term focus - Ad-hoc-news.de
- 2026-07-21ETFs Investing in Shionogi & Co Ltd Unsponsored ADR Stocks - TradingView
- 2026-07-20FDA accepts Shionogi’s sNDA for Fetroja - The Pharma Letter
- 2026-07-20Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth - Yahoo Finance
- 2026-07-20Shionogi (TSE:4507) Looks Cheap After FDA Accepts Cefiderocol Pediatric sNDA - simplywall.st
- 2026-07-20Shionogi (TSE:4507) Looks Cheap After FDA Accepts Cefiderocol Pediatric sNDA - simplywall.st
- 2026-07-18FDA Accepts Shionogi's sNDA to Expand Cefiderocol Use to Pediatric Patients With Drug-Resistant Gram-Negative Infections - Contagion Live
- 2026-07-17Shionogi Wins FDA Acceptance for Pediatric Fetroja Filing - International Business Times
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.